You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk

https://doi.org/10.1136/ebm.11.6.178

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–37.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In postmenopausal women, does raloxifene reduce the risks of coronary events and invasive breast cancer?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Internal medicine ★★★★★★☆ Cardiology ★★★★★★☆ Geriatrics ★★★★★★☆ Haematology ★★★★★★☆ Oncology ★★★★★★☆ Rheumatology ★★★★★★☆ Gynaecology ★★★★★★☆ Endocrine ★★★★★☆☆

    METHODS

    Embedded ImageDesign:

    randomised placebo controlled trial (Raloxifene Use for The Heart [RUTH] trial).

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (clinicians, participants, outcome assessors, laboratory staff, and sponsor).*

    Embedded ImageFollow up period:

    median 5.6 years.

    Embedded ImageSetting:

    177 centres in 26 countries worldwide.

    Embedded ImageParticipants:

    10 101 postmenopausal women ⩾55 years of age (mean 68 y) with or at increased risk of coronary heart disease. Exclusion criteria included recent myocardial infarction (MI) or revascularisation procedure; history of cancer, venous thromboembolism (VTE), heart failure, or chronic liver or renal disease; life expectancy <5 …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr E Barrett-Connor, University of California, San Diego, La Jolla, CA, USA. ebarrettconnor{at}ucsd.edu

    • Source of funding: Eli Lilly.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 191-191 Published Online First: 30 Nov 2006. doi: 10.1136/ebm.11.6.191-a